scholarly journals Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome

2020 ◽  
Vol 2020 ◽  
pp. 1-7 ◽  
Author(s):  
Hande Erman ◽  
Engin Beydogan ◽  
Seher Irem Cetin ◽  
Banu Boyuk
Keyword(s):  
Metabolic Syndrome ◽  
Fatty Liver ◽  
Liver Steatosis ◽  
Cutoff Point ◽  
Healthy Controls ◽  
Roc Curve Analysis ◽  
Cross Sectional ◽  
Nonalcoholic Fatty Liver ◽  
Fatty Liver Index ◽  
Hepatic Steatosis Index

Background. Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases, which has recently been mentioned as an independent cardiovascular risk factor. Objectives. Endocan is a novel molecule of endothelial dysfunction. We aimed to evaluate the associations of serum endocan levels with the hepatic steatosis index (HSI), fatty liver index (FLI), and degrees of hepatosteatosis in patients with metabolic syndrome with NAFLD. Design and Setting. This cross-sectional prospective study was performed in the outpatient clinic of an internal medicine department. Methods. The study included 40 patients with metabolic syndrome with NAFLD as noted using hepatic ultrasound and 20 healthy controls. Secondary causes of fatty liver were excluded. FLI and HSI calculations were recorded. Serum endocan level values were obtained after overnight fasting. Results. Higher values of HSI and FLI were found in the NAFLD groups than in the control groups (p<0.001). Five (12.5%) of 20 patients with liver steatosis had grade 1 liver steatosis, 15 (37.5%) patients had grade 2 liver steatosis, and 20 (50%) patients had grade 3 liver steatosis. Serum endocan levels were lower in patients with NAFLD compared with the healthy controls (146.56±133.29 pg/mL vs. 433.71±298.01 pg/mL, p<0.001). ROC curve analysis suggested that the optimum endocan value cutoff point for NAFLD was 122.583 pg/mL (sensitivity: 71.79%, specificity: 90%, PPV: 93.3%, and NPV: 62.1%). Conclusion. Serum endocan concentrations are low in patients with NAFLD, and the optimum cutoff point is 122.583 pg/mL. HSI and FLI were higher in patients with NAFLD; however, there was no correlation with serum endocan.

scholarly journals Role of vascular endothelial growth factor in the pathogenesis of hepatic steatosis and dyslipidemia

2020 ◽  
pp. 31-36
Author(s):  
И.Л. Гуляева ◽  
И.А. Булатова ◽  
Л.Д. Пестренин
Keyword(s):  
Metabolic Syndrome ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Low Density Lipoproteins ◽  
Control Group ◽  
Low Density ◽  
Very Low Density Lipoproteins ◽  
Fatty Liver Index ◽  
Nonalcoholic Hepatic Steatosis ◽  
Hepatic Steatosis Index

Цель исследования - изучение роли васкулоэндотелиального фактора роста в патогенезе неалкогольного стеатоза печени и дислипидемии при метаболическом синдроме. Методика. Обследовано 35 пациентов с неалкогольным стеатозом печени, в том числе 22 женщины и 13 мужчин. Группу контроля составили 12 сопоставимых по полу и возрасту лиц без патологии печени и признаков метаболического синдрома. Наличие жирового гепатоза подтверждали методом ультразвукового исследования. У пациентов с патологией печени рассчитывали индексы-предикторы стеатоза: Fatty Liver Index (FLI) и Hepatic Steatosis Index (HSI). У всех участников исследования определяли уровни провоспалительных цитокинов и васкулоэндотелиального фактора роста (ВЭФР), оценивали также липидный спектр крови и функциональные печеночные пробы. Результаты. У пациентов со стеатозом печени наблюдалось значимое увеличение уровней провоспалительных цитокинов, ВЭФР, общего холестерина и липопротеинов низкой и очень низкой плотности. Индекс атерогенности также был значимо выше, чем в контрольной группе. Концентрация ВЭФР положительно коррелировала с показателями окружности талии, тимоловой пробы, уровнями общего холестерина, липопротеинов низкой плотности и индексом атерогенности. Чувствительность FLI составила 91,4%, HSI - 97,1%. При этом, значения FLI и HSI значимо коррелировали с уровнем ВЭФР. Заключение. Полученные данные позволяют предположить, что ВЭФР, один из основных маркеров эндотелиальной дисфункции, может играть немаловажную роль в патогенезе неалкогольного стеатоза печени и дислипидемии у пациентов с метаболическомим синдромом The aim of the study was to assess the role of vascular endothelial growth factor (VEGF) in the pathogenesis of nonalcoholic hepatic steatosis and dyslipidemia in patients with signs of metabolic syndrome. Methods. 35 patients with nonalcoholic fatty liver disease, including 22 women and 13 men, were evaluated. The sex- and age-matched control group consisted of 12 people without liver pathology and metabolic syndrome criteria. Presence of hepatic steatosis was confirmed by an ultrasound examination. The Fatty Liver Index (FLI) and the Hepatic Steatosis Index (HSI) were calculated for patients with hepatic steatosis. Concentrations of proinflammatory cytokines and VEGF were measured for all participants. Also, blood biochemistry, including the lipid profile and liver function tests, was analyzed. Results. In patients with hepatic steatosis, levels of proinflammatory cytokines and VEGF were significantly increased. Also, concentrations of total cholesterol, low-density lipoproteins, and very low-density lipoproteins were higher in patients with the liver pathology than in the control group. Atherogenic coefficient was increased in hepatic steatosis. Significant correlations were observed between VEGF and waist circumference, thymol test, total cholesterol, low-density lipoproteins, very low-density lipoproteins, and atherogenic coefficient. Sensitivity of FLI and HIS was 91.4% and 97.1%, respectively. Also, FLI significantly correlated with HSI and VEGF level. Conclusion. The study suggested that VEGF, of the main markers of endothelial dysfunction, plays an important role in the pathogenesis of nonalcoholic hepatic steatosis and dyslipidemia in patients with signs of metabolic syndrome.

scholarly journals Increased Level of Serum Ceramides Correlate with Liver Steatosis, Hba1c and Cholesterol in Obese Patients

2020 ◽  
Vol 4 (1) ◽  
Keyword(s):  
Metabolic Syndrome ◽  
Metabolic Diseases ◽  
Glycosylated Hemoglobin ◽  
Liver Steatosis ◽  
Metabolic Parameters ◽  
Control Group ◽  
Obese Patients ◽  
Active Components ◽  
Cross Sectional ◽  
Nonalcoholic Fatty Liver

Objective: Sphingolipids including ceramides are biological active components of all cell membranes. They play a great role in cell interconnections in the process of proliferation, maturation, cell apoptosis and any fluctuations of their level can lead to development of metabolic diseases such as type 2 diabetes (T2D) and nonalcoholic fatty liver disease. Nevertheless, there is lack of information about what type of ceramides play a role in aforementioned diseases. Here we investigated the relationship between the serum level of some type of ceramides and parameters of metabolic syndrome that is commonly present in obese patients. Design: We performed cross-sectional study in two groups. One of them was control group – lean healthy people (n=10, body mass index, BMI 21, 2±1, 89) and the second group included patients with the obesity (n=24, BMI 33, 9±3, 1). We quantified the levels of serum ceramide by liquid chromatography-mass spectrometry, analyzed the parameters for insulin resistance, liver function and lipid metabolism by biochemical blood test. Results: The subjects with obesity had elevated level of ceramide C16:0, C18:0, C24:0 comparing with control group (p<0,001). As results of our study, we found correlation of the level ceramide C16:0, C18:0, C24:0 with the results of steatometry and some metabolic parameters (glycosylated hemoglobin (Hb A1C), cholesterol). Conclusion: These results demonstrate that obese subjects had increased level of ceramide C16:0, C18:0, C24:0 that correlated with some metabolic parameters supposedly recognizing them as new biomarkers of metabolic syndrome.

Afamin predicts the prevalence and incidence of nonalcoholic fatty liver disease

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Niina Pitkänen ◽  
Armin Finkenstedt ◽  
Claudia Lamina ◽  
Markus Juonala ◽  
Mika Kähönen ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Population Based ◽  
Healthy Controls ◽  
Nonalcoholic Fatty Liver ◽  
Age And Sex

Abstract Objectives In the general population, increased afamin concentrations are associated with the prevalence and incidence of metabolic syndrome as well as type 2 diabetes. Although metabolic syndrome is commonly associated with nonalcoholic fatty liver disease (NAFLD), there exist no information on afamin and NAFLD. Methods Afamin concentrations were cross-sectionally measured in 146 Austrian patients with NAFLD, in 45 patients without NAFLD, and in 292 age- and sex-matched healthy controls. Furthermore, the feasibility of afamin to predict incident NAFLD was evaluated in 1,434 adult participants in the population-based Cardiovascular Risk in Young Finns Study during a 10-year follow-up. Results Median afamin concentrations were significantly higher in NAFLD patients (83.6 mg/L) than in patients without NAFLD (61.6 mg/L, p<0.0001) or in healthy controls (63.9 mg/L, p<0.0001). In age- and sex-adjusted logistic regression analyses a 10 mg/L increase of afamin was associated with a 1.5-fold increase of having NAFLD as compared with patients without NAFLD and the risk was even two-fold when compared with healthy controls. In the population-based cohort, afamin concentrations at baseline were significantly lower in participants without NAFLD (n=1,195) than in 239 participants who developed NAFLD (56.5 vs. 66.9 mg/L, p<0.0001) during the 10-year follow up, with highest afamin values observed in individuals developing severe forms of NAFLD. After adjustment for several potentially confounding parameters, afamin remained an independent predictor for the development of NAFLD (OR=1.37 [95% CI 1.23–1.54] per 10 mg/L increase, p<0.0001). Conclusions Afamin concentrations are increased in patients with NAFLD and independently predict the development of NAFLD in a population-based cohort.

scholarly journals Nonalcoholic fatty liver disease and familial Mediterranean fever: Are they related?

2012 ◽  
Vol 140 (9-10) ◽  
pp. 589-594 ◽  
Author(s):  
Cihat Sarkis ◽  
Erkan Caglar ◽  
Serdal Ugurlu ◽  
Emel Cetinkaya ◽  
Nilüfer Tekin ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Liver Disease ◽  
Familial Mediterranean Fever ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Patient Group ◽  
Fatty Liver Disease ◽  
Healthy Controls ◽  
Nonalcoholic Fatty Liver ◽  
Mediterranean Fever

Introduction. Familial Mediterranean fever (FMF) is a periodic febrile disease characterized by acute recurrent episodes of serositis. Liver disease is not considered a part of the spectrum of clinical manifestations of FMF. Objective. The purpose of this study was to characterize the nonalcoholic fatty liver disease (NAFLD) that could be associated with familial Mediterranean fever (FMF). Methods. Clinical findings and treatment information of the patients with FMF were obtained from outpatient files. Weight, height, hip and waist circumference, blood pressure, blood C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, glucose, low-density lipoprotein (LDL), highdensity lipoprotein (HDL), triglycerides (TG), creatinine, alanine aminotransferase (ALT), and insulin levels were determined in all subjects, and additionally liver ultrasonography was performed for signs of hepatosteatosis. Results. Fifty-two age and gender matched patients with FMF, and 30 healthy controls were included in the study. The prevalence of metabolic syndrome in the patient group was determined to be significantly higher in the patient group compared to the healthy group. When FMF patients with and without hepatosteatosis were compared, the prevalence of metabolic syndrome was determined to be 6 vs. 3, respectively (p<0.001). Eleven patients with FMF were found to have grade 1-2 hepatosteatosis, and only 6 of healthy subjects had grade 1 hepatoseatosis (p=0.901). Conclusion. When compared with healthy controls, we found the prevalence of NAFLD was not increased in patients with FMF.

scholarly journals Dietary Sources of Fructose and Its Association with Fatty Liver in Mexican Young Adults

Nutrients ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 522 ◽  
Author(s):  
Alejandra Cantoral ◽  
Alejandra Contreras-Manzano ◽  
Lynda Luna-Villa ◽  
Carolina Batis ◽  
Ernesto Roldán-Valadez ◽  
...  
Keyword(s):  
Young Adults ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Liver Fat ◽  
Cross Sectional ◽  
Alcoholic Fatty Liver ◽  
Sweetened Beverages ◽  
Fatty Liver Index ◽  
Hepatic Steatosis Index ◽  
Sectional Analysis

Fructose intake has been associated with non-alcoholic fatty liver disease (NAFLD). The objective of this study was to assess the consumption of dietary fructose according to: 1) classification of hepatic steatosis by two indexes and 2) diagnosis of NAFLD by MRI. We conducted a cross-sectional analysis among 100 young adults from Mexico City. The Hepatic Steatosis Index (HSI) and the Fatty Liver Index (FLI) were estimated using Body Mass Index (BMI), waist circumference, and fasting concentrations of glucose, triglycerides, and hepatic enzymes (ALT, AST, GGT). A semi-quantitative food frequency questionnaire was administered to obtain dietary sources of fructose. We estimated the concordance between the hepatic indices and NAFLD and the correlation between the index scores and the percentage of liver fat. Eighteen percent presented NAFLD; 44% and 46% were classified with hepatic steatosis according to HSI and FLI, respectively. We compared dietary intake of fructose by each outcome: HSI, FLI, and NAFLD. Sugar-sweetened beverages (SSB) and juices were consumed significantly more by those with steatosis by FLI and NAFLD suggesting that SSB intake is linked to metabolic alterations that predict the risk of having NAFLD at a young age.

scholarly journals Validation of Fatty Liver Index as a Marker for Non-Alcoholic Fatty Liver Disease

2021 ◽  
Vol 21 (2) ◽  
pp. 56-62
Author(s):  
Seong-Won Park ◽  
A-Lum Han
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Health Examination ◽  
Cross Sectional ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Liver Index ◽  
Fatty Liver Index ◽  
Alcoholic Fatty Liver Disease

Background: Many studies have been conducted to validate fatty liver index (FLI) as a marker for non-alcoholic fatty liver disease (NAFLD). However, there are insufficient data in Korea to verify the usefulness of FLI, and the results of these studies are contradictory. This study aimed to validate FLI as a marker for NAFLD in Korea. For better accuracy, computed tomography (CT) scan was used instead of ultrasound scan.Methods: A cross-sectional analysis was performed in 785 subjects who participated in a health examination. The participants were divided according to presence of NAFLD, which was determined by abdominal CT. Frequency analysis was performed on all results. The chi-square test and independent t-test were used to compare the differences between the non-NAFLD group and the NAFLD group in terms of general characteristics and blood tests. The ability of the FLI to detect (nonalcoholic) fatty liver was assessed using area under the receiver operator characteristic (AUROC) curve analysis.Results: FLI was significantly higher in the NAFLD group (42.48±27.63) than in the non-NAFLD group (22.59±20.05) (P<0.0001). The algorithm for FLI had a better AUROC of 0.696 (95% confidence interval, 0.649-0.742) than any other variable in the prediction of NAFLD.Conclusions: FLI is a marker that can be used as a simple and cost-effective tool to screen for NAFLD.

scholarly journals Cutoff Point of TyG Index for Metabolic Syndrome in Brazilian Farmers

2021 ◽  
Vol 5 (Supplement_2) ◽  
pp. 1031-1031
Author(s):  
Júlia Ferreira ◽  
Eliana Zandonade ◽  
Olívia Bezerra ◽  
Luciane Salaroli
Keyword(s):  
Metabolic Syndrome ◽  
Area Under The Curve ◽  
Epidemiological Studies ◽  
Cutoff Point ◽  
Youden Index ◽  
Roc Curve Analysis ◽  
Cross Sectional ◽  
Insulin Resistant ◽  
Tyg Index ◽  
Unified Health System

Abstract Objectives The determination of Insulin Resistance (IR) requires sophisticated and costly methods, for this reason the TyG Index was proposed. However, there are still no studies in Brazil using Metabolic Syndrome (MetS) as a predictor of IR. Thus, the aim of this study was to determine the cutoff point for TyG as one of the indirect indices for MetS in a rural Brazilian population. Methods Cross-sectional observational epidemiological study conducted in a rural municipality in Brazil. The study population were 790 adult family farmers. The TyG index was calculated: Ln [fasting triglycerides (mg/dL) x fasting glycemia (mg/dL)]/2, and MetS was defined using the NCEP-ATPIII and IDF criteria. To describe the study variables, measures of central tendency and dispersion measures were used. For association analysis, the Mann-Whitney U test was used and the comparison between means was made using the Kruskal-Wallis test. For correlations, Spearman's correlation test was used. The cutoff values of TyG Index for MetS were obtained using the Receiver Operating Characteristic (ROC) curve analysis with the area under the curve (AUC) and the Youden Index. Results The median TyG values were higher among individuals diagnosed with MetS (P &lt; 0.001), and increased according to the aggregation of the components of MetS. All MetS components were correlated with TyG (P &lt; 0.001). The AUC for NCEP was 0.873 (0.848–0.896; P &lt; 0.001), with Youden's cutoff point of Ln 4.52 (sensitivity: 84.30%; specificity: 75.75%). The AUC for IDF was 0.867 (0.842–0.890; P &lt; 0.001), with Youden's cutoff point of Ln 4.55 (sensitivity: 80.0%; specificity: 79.82%). A cutoff point of Ln 4.52 was defined. Conclusions The TyG Index is a reliable marker for identifying insulin-resistant individuals, and correlates with the metabolic changes present in MetS. A cutoff point of Ln 4,52 has good sensitivity and specificity in both diagnostic criteria of MetS, being useful both in clinical practice and epidemiological studies, and can represent an important tool for the creation of protocols for promotion, protection and recovery health of rural populations. Funding Sources Research Program of the Unified Health System (PPSUS), through the notice FAPES/CNPq/Decit-SCTIE-MS/SESA No. 05/2015 – PPSUS.

Sign in / Sign up

Export Citation Format

Share Document